Cerebrolysin vs Dihexa: Clinical Veteran vs Lab Superstar
Here is how these two compounds compare — based on published research, not marketing claims.
Cerebrolysin
658
Indexed Studies
Human Trials
Evidence Level
Yes
Human Trials
Not Approved
FDA Status
Dihexa
11
Indexed Studies
Animal Studies
Evidence Level
None
Human Trials
Not Approved
FDA Status
PSI OVERVIEW
Here is the key difference between these compounds and what it means for the research.
This comparison illustrates the gap between clinical validation and preclinical excitement. Cerebrolysin has been used clinically for neurological conditions in over 40 countries for decades. Dihexa produced extraordinary results in animal models of cognitive impairment but has never been tested in a single human. One has treated real patients. The other has treated real mice.
Key Differences
| Attribute | Cerebrolysin | Dihexa |
|---|---|---|
| Evidence Level | Human Trials | Preclinical |
| Category | Neurotrophic Peptide Mixture | Angiotensin IV Analog |
| Human Data | Hundreds of publications. Phase III trials for stroke. Regulatory approval in multiple countries. PSI rates L3. | Zero. Approximately 11 papers from essentially one research group. All animal and in vitro. |
| Safety Profile | Approved in 40+ countries. Decades of clinical safety data. IV and IM administration. Generally well-tolerated. | No human safety data. Very potent compound. HGF pathway involvement raises theoretical growth factor concerns. |
| Key Limitations | Not FDA-approved. Multi-component mixture complicates mechanistic study. Some trials showed modest effect sizes. | No human data. Single-group research. Theoretical safety concerns. Extraordinary claims require extraordinary evidence. |
Mechanism Comparison
HOW THEY WORK
These compounds work through different biological pathways. Here is how each one operates at the cellular level.
Cerebrolysin
A standardized mixture of brain-derived neuropeptides mimicking BDNF, NGF, GDNF, and CNTF. Supports neuronal survival, synaptic plasticity, and recovery after brain injury.
Dihexa
Activates HGF/c-Met signaling to promote synaptogenesis. In animal models, it restored cognitive function at doses described as millions of times more potent than BDNF for new synapse formation.
Cerebrolysin provides a cocktail of established neurotrophic factors. Dihexa activates a single powerful growth pathway (HGF/c-Met). Cerebrolysin is a broad nourishment. Dihexa is a concentrated signal. Cerebrolysin has been shown to help neurons recover. Dihexa has been shown to build new synapses in mice.
Research Evidence
RESEARCH EVIDENCE
Between these compounds, researchers have published over 669 indexed studies. Here are the key findings.
The gap could not be wider. Cerebrolysin is L3 with regulatory approval in 40+ countries, hundreds of publications, and real clinical use. Dihexa is L1 with 11 papers and zero human data. This is decades of clinical experience versus a laboratory observation.
For evidence-based neuroprotection, cerebrolysin has extensive clinical validation.
For theoretical synaptogenesis research, dihexa's animal data is scientifically interesting.
For any clinical decision, cerebrolysin is the only option with human experience.
Dihexa represents potential. Cerebrolysin represents evidence.
Key Limitations
- •This comparison is inherently asymmetric — one is established, the other is preclinical.
- •Dihexa's extraordinary potency claims come from a single research group.
- •Animal cognitive models do not reliably predict human cognitive outcomes.
- •Cerebrolysin's multi-component nature and dihexa's single-mechanism focus make different kinds of comparison difficult.
PSI Verdict
SUPPORTED BY EVIDENCE
Cerebrolysin improves neurological outcomes in stroke and TBI patients across multiple clinical trials with regulatory approval in 40+ countries. Dihexa promotes synaptogenesis at extraordinary potency in rodent models of cognitive impairment.
NOT YET ESTABLISHED
Dihexa has never been tested in humans. Whether its animal results translate is completely unknown. The safety of chronic HGF/c-Met activation in humans is unstudied.
CONFIDENCE LEVEL
High for cerebrolysin within its clinical applications. Very low for dihexa as a clinical prospect. If a human patient needs neuroprotection today, cerebrolysin has the track record. Dihexa is a lab observation, not a clinical option.
Community Discussion
WHAT THE COMMUNITY IS SAYING
PSI monitors discussions across peptide research and biohacking communities. These are reported experiences, not clinical evidence.
Cerebrolysin
"Cerebrolysin is used in hospitals across Europe and Asia"Supported by evidence
"Cerebrolysin improved my cognitive function after brain injury"Plausible — clinical data exists
Dihexa
"Dihexa is millions of times more potent than BDNF"Technically accurate but misleading
"Dihexa is the strongest nootropic available"Insufficient evidence
"I'm worried about dihexa and cancer risk"Legitimate concern
Safety Comparison
SAFETY PROFILE
What is currently known about the safety of each compound based on available research.
Cerebrolysin
Approved in 40+ countries. Decades of clinical safety data. IV and IM administration. Generally well-tolerated.
Dihexa
No human safety data. Very potent compound. HGF pathway involvement raises theoretical growth factor concerns.
Cerebrolysin has decades of clinical safety data. Dihexa has none. The HGF/c-Met pathway that dihexa activates is involved in cell growth regulation, including cancer biology.
WHAT THE RESEARCH SUGGESTS
Cerebrolysin is the evidence-based option. Dihexa is the exciting speculation. Many exciting speculations in neuroscience have failed to translate to humans.
Frequently Asked Questions
Explore Each Compound
For the full evidence profile, PSI Verdict, and indexed research data, visit each compound's dedicated page.
Looking for a physician experienced with peptide therapy?
Every physician in the PSI directory is individually verified for active licensure, board certification, and clinical peptide experience.
Browse the PSI Physician Directory →Explore Individual Research Pages
Related PSI Resources
Medical Disclaimer
This content is for educational and informational purposes only and does not constitute medical advice. The information presented reflects published research as indexed by PSI and should not be used to make treatment decisions. Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment.